We previously reported the diagnostic efficacy of the age-and prostate volume-adjusted prostate biopsy method (the adjusted biopsy method). Here, we developed a new nomogram for predicting cancer probability at initial biopsy using the adjusted method.
Introduction
Recently, the European Randomized Study of Screening for Prostate Cancer 1 and the subsequent Gö teborg randomized population-based study of screening for prostate cancer 2 provided level 1 evidence regarding the effectiveness of PSA screening, revealing a significant mortality reduction of 20% after 9 years and 44% after 14 years median follow-up. On the other hand, the drawbacks of screening for prostate cancer are overdetection and overtreatment by intensive screening exposure and invasive treatment strategies. Therefore, it is important to minimize the overdetection of indolent cancer and the underdetection of significant cancer in the screening system.
Although the establishment of optimal biopsy methods is a high-priority issue in this field, there is still controversy regarding the ideal biopsy strategy. Biopsy schemes taking the natural history of prostate cancer into consideration may be acceptable. Vashi et al. 3 introduced the life expectancy-and prostate volume (PV)-adjusted biopsy scheme. They estimated cancer volumes, which should be detected in each age group, based on the life expectancy, average tumor doubling time and life-threatening cancer volume. They calculated necessary biopsy-core numbers, stratified according to age group and PV of the patients. Previously, we developed a Japanese version of the age-and PV-adjusted biopsy method (the adjusted biopsy method), and reported excellent diagnostic accuracy in an initial 100 patients. 4 The adjusted biopsy method may be theoretically reasonable, but the objective validity of the biopsy concept has not yet been investigated in a large cohort.
Several nomograms to predict cancer probability at initial prostate biopsy have been reported in Western countries and Japan. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Even in internally or externally validated nomograms, the feasibility of logistic regressionbased nomograms in actual individual urological clinics should be evaluated from the viewpoints of the acceptability of clinical factors taken into account in the nomogram and homogeneity of biopsy schemes between clinics and the institutions providing the nomograms. The life expectancy-and PV-adjusted biopsy may be unique, and could be difficult to adjust to any previously published nomogram. Thus, in the present study, we developed a specific nomogram to predict cancer probability at initial biopsy using a database of consecutive patients from Gunma University Hospital. Furthermore, we compared the predictive accuracy of the newly developed nomogram with the 'Prostate Risk Indicator ', 15 which is available at the website of the European Association of Urology. We also validated the new model using the biopsy data from two affiliated hospitals where the same adjusted biopsy method has been used.
Patients and methods
The study population included 1059 consecutive patients from the Gunma University Hospital who underwent transrectal ultrasonography (TRUS)-guided systematic prostate biopsy as a first biopsy between March 2002 and November 2010. All participants underwent prostate biopsy with the adjusted method, and the number and locations of biopsy cores were determined by the nomogram and the diagram described previously. 4 In summary, the number of biopsy cores for the adjusted method was set according to life expectancy and PV in each subject. First, the tumor volume in which a diagnosis would be necessary at each age was estimated using data on average life expectancy, tumor doubling time and life-threatening tumor volume. We used life expectancy data from a life-table of Japanese in 1998, a tumor doubling time of 4 years based on the findings of Schmid et al., 16 and a tumor volume that influenced death at 20 cm 3 based on the study by Dugan et al.
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Then, the tumor volume that should be discovered in each age (Y cm 3 ) could be estimated using the following formula: Y ¼ 20/2 (X/4) , where X is a man's life expectancy. Simultaneously, the PV was calculated by TRUS, and the necessary number of biopsies for the diagnosis relative to tumor volume was set based on the study by Vashi et al. 3 Then, the necessary number of biopsies for each age range and PV was determined.
The biopsy indications at Gunma University Hospital were PSA above the upper limit of the age-adjusted reference range of PSA 18 primarily from the screening program in our province or abnormal findings on digital rectal examination (DRE)/TRUS in patients with some lower urinary symptoms visiting the outpatient clinic. The highest PSA level of a negative biopsy result was 40 ng ml À1 in this cohort. Thus, we decided to develop the nomogram to estimate the probability of prostate cancer with this biopsy scheme in patients with PSA levels p40.0 ng ml
À1
. Findings on DRE and TRUS were recorded and PVs were determined before the first biopsy. Serum PSA levels were measured by the E-test Tosoh II PSA assay (Tosoh, Tokyo, Japan). PV was calculated by the formula: 0.523 Â width Â length Â height determined by TRUS. Pathological findings of patients diagnosed with prostate cancer were investigated, including the percentage of positive biopsy cores, Gleason score, cancer length in biopsy specimens, percentage of cancer occupancy (cancer length/total biopsy core length) and whether they had insignificant cancer (that is, Gleason score p6, one positive biopsy core and cancer length o3 mm), by two urological pathologists.
To develop the nomogram, data of the initial 849 participants were used as a training set, and data from the remaining 210 subjects were used for internal validation. The data were analyzed using the SPSS software (ver. 19.0; SPSS, Chicago, IL, USA). Age, PSA level, PV and findings of DRE and TRUS were used as factors to estimate the risk of positive biopsy through univariate logistic regression analysis. Finally, stepwise multiple regression analysis was performed to determine independent predictive factors, and a nomogram for predicting cancer probability of patients undergoing initial biopsy using the adjusted method was developed. In the stepwise multiple regression analysis, a suspicious DRE and/or TRUS was coded as 1, and a non-suspicious DRE and/or TRUS as 0. The other clinical factors including PSA level, PV and age were considered continuous variables. Extracted independent factors that could predict prostate cancer were evaluated for their power to distinguish the significance of prostate cancer by the Mann-Whitney U-test for continuous variables or the w 2 test for categorical variables. For internal validation, the area under the curve (AUC) of the receiver operating characteristic (ROC) curve (AUC-ROC) on the newly developed nomogram was determined using the remaining 20% of the data from Gunma University. To investigate the predictive accuracy of the new model for Japanese males who underwent life expectancy-and PV-adjusted biopsy methods, the AUC-ROC of single independent clinical factors and the 'Prostate Risk Indicator' 15 as a representative of widely available nomograms were estimated using the development data set.
For external validation of the newly developed nomogram, clinical data sets from two affiliated hospitals, where the same adjusted biopsy method has been adopted, were collected and the validity was analyzed by a calibration plot using the 'R' software (http:// www.r-project.org/). Furthermore, the predictive accuracy of the newly developed nomogram was also compared with the 'Prostate Risk Indicator' using the two external data sets.
Results
The mean (±s.d.) age, PSA level and PV of all 1059 participants were 67.9 ± 7.8 years, 9.3 ± 8.0 ng ml À1 and 34.3±15.5 cm 3 , respectively. Of 1059 participants, 523
Predictive nomogram for initial prostate biopsy M Nomura et al (49.4%) were diagnosed with prostate cancer. The mean (±s.d.) age, PSA level and PV were 69.7±7.3 years, 11.6 ± 8.4 ng ml À1 and 29.2 ± 12.9 cm 3 in men with prostate cancer, and 66.3±8.0 years, 7.1±4.4 ng ml
À1
and 39.1 ± 16.2 cm 3 in those without prostate cancer, respectively. The percentages of patients with abnormal findings on DRE and TRUS were 39.8% and 41.2%, respectively. The numbers of biopsy cores taken (mean ± s.d.) were 12.6 ± 5.7 cores in all patients and 13.0±4.9 cores in those with PSA levels p10 ng ml
. The details of the pathological features in patients diagnosed with prostate cancer at Gunma University Hospital are shown in Table 1 . Overall, the percentage of patients with Gleason scores of 8-10 was high at 30.6%. Approximately 65% of patients had positive biopsy cores 420%, and about 54% of patients had a total cancer length in biopsy specimens of over 10 mm. Only 6.1% of patients were classified into the insignificant cancer category. The percentage of patients with insignificant cancer, low-grade cancer or small-volume cancer decreased with a higher PSA range.
The univariate analysis showed significant correlations between positive biopsy rate and each parameter ( Table 2) . A stepwise multivariate analysis indicated that the findings on TRUS were not significantly correlated (P ¼ 0.100), but that the other four factors were significant factors (Table 3) . A logistic regression-based nomogram using those four independent risk factors to predict cancer probability at initial biopsy using the adjusted method was developed ( Figure 1 ). Internal validation was performed using the remaining 20% of the data. The ROC analysis indicated the predictive significance of the newly developed nomogram compared with all single clinical factors, including PSA, age, PV and DRE findings. The AUC-ROC for the newly developed nomogram, PSA, age, PV and DRE findings are shown in Table 4 . The AUC-ROC was the largest for the new model at 0.831 compared with four single independent clinical factors. The AUC-ROC for the 'Prostate Risk Indicator' was also estimated using the 210 data set for internal validation. The AUC-ROC of the 'Prostate Risk Indicator' was the second largest at 0.820, closely following the newly developed nomogram.
Four independent predictive factors (age, PSA, DRE findings and PV) were compared between patients classified with significant prostate cancer and those with insignificant cancer. Age (P ¼ 0.15473), PSA (P ¼ 0.26255) and PV (P ¼ 0.05392) were not significantly different between these groups. Only the DRE findings were significantly different between patients with significant prostate cancer and those with indolent cancer (P ¼ 0.02613).
External validation was performed using data from two affiliated hospitals. Baseline characteristics of the patients from the two hospitals are shown in Table 5 . As shown in Figure 2 , calibration plots of the present nomogram showed a good correlation between predicted and actual cancer probability. AUC-ROC for the new model using the external data sets at Gunma Cancer Center and Tone Chuo Hospital, respectively, was larger at 0.780 and was comparable at 0.791 compared with that for the 'Prostate Risk Indicator', which was 0.764 and 0.795, respectively. Predictive
Discussion
In the present study, we developed a nomogram to predict prostate cancer at initial biopsy using the ageand PV-adjusted biopsy method. The present nomogram yielded a more accurate positive prediction rate than any single significant parameter (that is, PSA level, PV findings or DRE findings). External validation was conducted using data from two affiliated hospitals to evaluate the efficacy of the present nomogram. We adopted the age-and PV-adjusted prostate biopsy method, and reported the diagnostic significance of this method previously. 4 In the present cohort, prostate cancer detection rates of patients with PSA p10 and 10-20 ng ml À1 were 40.3% and 46.2%, respectively. Although it is difficult to compare various biopsy methods in terms of positive biopsy rate among previous studies because of differences in patient clinical backgrounds even in the same PSA range and possible differences in compliance of candidates for prostate biopsies at institutions (that is, selection bias during institutional decision-making on biopsy indications), the positive biopsy rates shown in the present study were comparable to or greater than those of previous studies from other institutes. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 19, 20 Previous studies have demonstrated that the use of additional lateral cores to the original sextant biopsy cores increased the detection rate of prostate cancer. Eskew et al. 19 reported the usefulness of 13-18-core biopsies using the five-region anatomical approach. Presti et al. 17 reported the efficacy of the 10-core biopsy method. Recent studies also validated the 10-12-core biopsy method. 21, 22 Eichler et al. 22 performed a meta-analysis to study the diagnostic accuracy of extended biopsy, and found that 12 cores with additional cores lateral to the standard sextant cores detected 31% more cancers. The authors did not find an additive effect of 18-24-core biopsy for cancer detection. Chun et al. 23 also reported that the optimal core number for initial biopsy was at least 10 but no more than 18. Alternatively, several groups have noted the need for more biopsy cores from larger glands. [24] [25] [26] Scattoni et al.
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found no significant differences in overall cancer detection rate between the 12-and 18-core regimens. The authors compared the cancer detection rates of both regimens stratified by PV, and their results indicated that the 18-core regimen detected more cancer in larger prostate glands. There has been no conclusive report regarding the optimal number or sites of prostate biopsy cores for the detection of cancer. However, it may be possible to perform more objective comparisons based on the theory of external validation. Comparison of the newly developed biopsy methods with widely accepted fundamental biopsy schemes can be performed by inputting the raw data into a published nomogram to predict cancer probability for the fundamental biopsy scheme, and then checking the validity of a newly developed method by calibration plot analysis. If the performance characteristic of the newly developed biopsy method is below (above) the 451 line, this would indicate that the new method is inferior (superior) to the fundamental biopsy scheme. Although biopsy compliance with a new biopsy method must be high to investigate its reliability using the above nomogram-based objective comparison, this would be a more objective and reasonable evaluation method than simple comparison of positive biopsy rates stratified by PSA range.
To optimize the number of biopsy cores, Vashi et al. and Ito et al. 4 developed mathematical models to calculate clinically significant cancer volumes. Remzi et al. 27 proposed the Vienna nomogram to optimize the biopsy core number, based on age and PV. Recently, Jiang et al. 28 also demonstrated the concept of the volume-to-biopsy ratio. Volume-to-biopsy ratio was defined as PV/biopsy Predictive nomogram for initial prostate biopsy M Nomura et al core number, and they found that a volume-to-biopsy ratio of four maintained high cancer detection rates without taking the need for an excessive number of biopsy specimens. In the present study, the mean ± s.d. core numbers were 12.6±5.7 and 13.0±4.9 cores in all patients and in patients with PSA levels p10.0 ng ml À1 , respectively. Our method yielded high detection rates of significant cancer in the present cohort. Based on the criteria reported by Bassler and co-workers 29 (that is, Gleason score p6, one core and o3 mm), only 6.1% of the detected cancers were considered insignificant. The adjusted method, taking life expectancy and PV into account, would contribute to reducing the overdetection of insignificant cancer without reducing the detection rate of significant cancer.
The use of multiple regression-based nomograms may minimize the number of unnecessary biopsies. Several nomograms to estimate the initial positive biopsy rate have been proposed. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Suzuki et al. 7 developed the Japanese version of the nomogram, and Kawamura et al. 12 updated the model using data from patients with PSA levels o10 ng ml
À1
. Kawakami et al.
11 developed a nomogram based on logistic regression models and also artificial neural network models in a Japanese population. Variables included in these models were age, PSA level, DRE findings and percentage free PSA (%fPSA). We did not include %fPSA in the present study. The public health insurance system in Japan has approved measurement of %fPSA in patients with suspicious physical findings for prostate cancer or elevated PSA levels. In the ordinary clinical setting in our community, %fPSA was not measured in some patients with indications for prostate biopsy. We recommend prostate biopsy for almost all men with PSA levels above the cutoff, regardless of %fPSA. The actual percentages of patients whose %fPSA was measured in the present Predictive nomogram for initial prostate biopsy M Nomura et al cohort were 75.5% and 76.5% for all patients and those with PSA levels p10.0 ng ml À1 , respectively. Furthermore, the percentages of participants in the two affiliated hospitals in whom %fPSA was measured were lower. To avoid bias, we did not include %fPSA in the present analysis. At Gunma University Hospital, we did not select patients who underwent prostate biopsy according to their %fPSA or investigational tumor markers, such as proPSA. Therefore, it would be possible to develop a version of the nomogram, including %fPSA and proPSA in the future.
In the present study, we enrolled patients with PSA levels p40 ng ml À1 . In the ordinary clinical setting, prostate biopsy is strongly recommended in patients with PSA levels of 20-40 ng ml À1 because the detection rate of prostate cancer is high at approximately 80%. Furthermore, the number of men in that PSA range has decreased, particularly in the United States and western Europe, where PSA screening is widely provided to the public. Alternatively, the exposure rate of PSA screening may still be low in Asian countries. Therefore, it may be reasonable to develop a predictive nomogram, including PSA levels between 20 and 40 ng ml À1 , to more accurately distinguish patients with prostate cancer from those with large BPH or chronic prostatitis.
Family history could be one of the important factors that should be considered in the predictive model for men who have suspicious prostate cancer clinical findings. However, the reliability of family history may be doubtful in areas where PSA screening is low because many men with screen-detectable prostate cancer could be missed. Therefore, we did not add family history to the model.
The AUC-ROC of the 'Prostate Risk Indicator' was somewhat inferior to the newly developed nomogram using the development data set in Gunma University Hospital or one external data set, or almost the same as the new nomogram using the other external data set. This may mean that racial difference is no longer so much significant after adjusting for PSA level, age, PV and DRE findings. Although the evidence of a racial difference is not supported by head-to-head comparative international collaborations, a previous international cooperative study of Dutch and Japanese males demonstrated that the risk of developing prostate cancer was not different at the same baseline PSA levels, suggesting that racial differences may affect the likelihood of developing prostate cancer in different PSA ranges. Alternatively, it should be considered that there is a difference in biopsy schemes based on the development of nomograms between the present nomogram and the 'Prostate Risk Indicator'. Generally, some differences in diagnostic accuracy may occur between different biopsy schemes. Therefore, the same AUC-ROC may not always indicate that the compatibility of different nomograms was acceptable. On the other hand, in general, a modest nomogram, which does not include subjective factors, would be preferred to complex one, if the predictive accuracy was almost the same. Nevertheless the present model does not include somewhat subjective findings on TRUS abnormality, which is necessary for the estimation by 'Prostate Risk Indicator', the predictive accuracy of the present simple and more objective nomogram could be excellent enough to contribute to accurate shared decision-making between doctors and men who are candidates for prostate biopsy. Concerning the excellent results of the present external validation of the new nomogram, men who are candidates for the life expectancy-and PV-adjusted biopsy scheme should use this specific nomogram rather than using nomograms based on other biopsy schemes.
Recently, Ohigashi et al. 30 reported a nomogram to predict the possibility of clinically significant prostate cancer based on the clinical data of patients undergoing radical prostatectomy. Significant tumors were defined as those with a tumor volume 40.5 ml and/or Gleason score of X7. Although the number of patients analyzed was small, their data demonstrated accurate rates of significant cancer detection based on pathological findings in radical prostatectomy specimens.
The nomogram newly developed in the present study may be easy to use in routine urological practice. However, independent clinical factors used in the present Minimizing the overdetection of clinically insignificant prostate cancer may be one of the most important clinical issues yet to be solved. Alternatively, we believe that the definition of what constitutes a clinically significant tumor based on pathological grade and tumor volume should be changed according to life expectancy. Therefore, we are currently planning to develop a nomogram, including additional clinical parameters such as transition-zone PV, %fPSA and proPSA, 31 to estimate the risk of having a clinically significant tumor, the definition of which takes the concept of life expectancy into account.
